About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Gland Pharma Ltd.
Change Company
BSE Code
543245
ISIN Demat
INE068V01023
Book Value
608.43
NSE Code
GLAND
Dividend Yield %
0.91
Market Cap
327511.06
P/E
28.83
EPS
68.96
Face Value
1
1 Week
1 Month
3 Months
6 Months
1 Year
08-Sep-2025
Gland Pharma informs about investor meetings
26-Aug-2025
Gland Pharma receives USFDA’s approval for Vasopr...
12-Aug-2025
Gland Pharma gets USFDA’s approval for Norepineph...
12-Aug-2025
Gland Pharma gets USFDA’s nod for Cangrelor for I...
12-Aug-2025
Gland Pharma informs about press release
06-Aug-2025
Gland Pharma informs about press release
06-Aug-2025
Gland Pharma shines on reporting 50% jump in Q1 c...
05-Aug-2025
Gland Pharma reports 50% jump in Q1 consolidated ...
01-Aug-2025
Clarification sought from Gland Pharma Ltd
31-Jul-2025
Gland Pharma informs about BRSR
14-Jul-2025
Gland Pharma gets GMP Compliance Certificate for ...
14-Jul-2025
Gland Pharma gains on getting GMP Compliance Cert...
03-Jul-2025
Grant Of Stock Options Under Gland Pharma Employ...
24-Jun-2025
Gland Pharma gets EIR from USFDA for Visakhapatna...
24-Jun-2025
Gland Pharma soars on getting EIR from USFDA for ...
Page
1
of
3
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.